A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, Emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy

Ian D. Davis, Lynette Kiers, Lachlan MacGregor, Michael Quinn, Joseph Arezzo, Michael Green, Mark Rosenthal, Michael Chia, Michael Michael, Peter Bartley, Leonie Harrison, Michael Daly

Research output: Contribution to journalArticle

64 Scopus citations

Fingerprint Dive into the research topics of 'A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, Emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy'. Together they form a unique fingerprint.

Medicine & Life Sciences